Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Jiang M, Strand DW, Franco OE, Clark PE, Hayward SW.

Differentiation. 2011 Nov-Dec;82(4-5):220-36. doi: 10.1016/j.diff.2011.05.008. Epub 2011 Jun 8. Review.

2.

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Nicholson TM, Ricke WA.

Differentiation. 2011 Nov-Dec;82(4-5):184-99. doi: 10.1016/j.diff.2011.04.006. Epub 2011 May 26. Review.

3.

Role of interleukins, IGF and stem cells in BPH.

McLaren ID, Jerde TJ, Bushman W.

Differentiation. 2011 Nov-Dec;82(4-5):237-43. doi: 10.1016/j.diff.2011.06.001. Epub 2011 Aug 23. Review.

4.

PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.

Vignozzi L, Gacci M, Cellai I, Morelli A, Maneschi E, Comeglio P, Santi R, Filippi S, Sebastianelli A, Nesi G, Serni S, Carini M, Maggi M.

Prostate. 2013 Sep;73(13):1391-402. doi: 10.1002/pros.22686. Epub 2013 Jun 13.

PMID:
23765639
5.

Chemokines and BPH/LUTS.

Macoska JA.

Differentiation. 2011 Nov-Dec;82(4-5):253-60. doi: 10.1016/j.diff.2011.04.003. Epub 2011 May 19. Review.

6.

Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia.

Wang Z, Olumi AF.

Differentiation. 2011 Nov-Dec;82(4-5):261-71. doi: 10.1016/j.diff.2011.04.004. Epub 2011 May 4. Review.

PMID:
21536370
7.

A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.

Oudot A, Oger S, Behr-Roussel D, Caisey S, Bernabé J, Alexandre L, Giuliano F.

BJU Int. 2012 Nov;110(9):1352-8. doi: 10.1111/j.1464-410X.2012.11085.x. Epub 2012 Mar 27.

8.

Hyperglycemia and insulin resistance and the risk of BPH/LUTS: an update of recent literature.

Breyer BN, Sarma AV.

Curr Urol Rep. 2014 Dec;15(12):462. doi: 10.1007/s11934-014-0462-x. Review.

9.

Metabolic syndrome and lower urinary tract symptoms: the role of inflammation.

Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, Tubaro A, Corona G, Rastrelli G, Santi R, Nesi G, Serni S, Carini M, Maggi M.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):101-6. doi: 10.1038/pcan.2012.44. Epub 2012 Nov 20.

PMID:
23165431
10.

Hypovitaminosis D is associated with lower urinary tract symptoms and benign prostate hyperplasia in type 2 diabetes.

Caretta N, Vigili de Kreutzenberg S, Valente U, Guarneri G, Pizzol D, Ferlin A, Avogaro A, Foresta C.

Andrology. 2015 Nov;3(6):1062-7. doi: 10.1111/andr.12092. Epub 2015 Sep 4.

11.

Urine chemokines indicate pathogenic association of obesity with BPH/LUTS.

Tyagi P, Motley SS, Kashyap M, Pore S, Gingrich J, Wang Z, Yoshimura N, Fowke JH.

Int Urol Nephrol. 2015 Jul;47(7):1051-8. doi: 10.1007/s11255-015-0992-2. Epub 2015 Apr 30.

12.

Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.

Vignozzi L, Gacci M, Maggi M.

Nat Rev Urol. 2016 Feb;13(2):108-19. doi: 10.1038/nrurol.2015.301. Epub 2016 Jan 12. Review.

PMID:
26754190
13.

Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network.

Lin-Tsai O, Clark PE, Miller NL, Fowke JH, Hameed O, Hayward SW, Strand DW.

Prostate. 2014 May;74(6):669-79. doi: 10.1002/pros.22785. Epub 2014 Feb 5.

14.

The role of prostate inflammation and fibrosis in lower urinary tract symptoms.

Bushman WA, Jerde TJ.

Am J Physiol Renal Physiol. 2016 Oct 1;311(4):F817-F821. doi: 10.1152/ajprenal.00602.2015. Epub 2016 Jul 20. Review.

15.

Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.

Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L.

BJU Int. 2013 Nov;112(7):990-7. doi: 10.1111/bju.12251. Epub 2013 Aug 13.

16.

Benign Prostatic Hyperplasia, Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: Is Metaflammation the Link?

Russo GI, Cimino S, Castelli T, Favilla V, Gacci M, Carini M, Condorelli RA, La Vignera S, Calogero AE, Motta F, Puzzo L, Caltabiano R, Morgia G.

Prostate. 2016 Dec;76(16):1528-1535. doi: 10.1002/pros.23237. Epub 2016 Jul 25.

PMID:
27458062
17.
18.

Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links.

He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):7-13. doi: 10.1038/pcan.2015.43. Epub 2015 Sep 22. Review.

19.
20.

Clinical significance of peripheral zone thickness in men with lower urinary tract symptoms/benign prostatic hyperplasia.

Kwon JK, Han JH, Choi HC, Kang DH, Lee JY, Kim JH, Oh CK, Choi YD, Cho KS.

BJU Int. 2016 Feb;117(2):316-22. doi: 10.1111/bju.13130. Epub 2015 Jun 3.

Supplemental Content

Support Center